EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

The Clinical Translation of α-humulene – A Scoping Review

Nishaanth Dalavaye iD, Martha Nicholas, Manaswini Pillai, Simon Erridge, Mikael H Sodergren

Planta Medica · 01.08.2024 · 90 (09) · 664-674

DOI: 10.1055/a-2307-8183 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Planta Medica, erschienen am 01.08.2024. Verfasst von Nishaanth Dalavaye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, UK. Hauptthemen laut MEDLINE: Monocyclic Sesquiterpenes, Oils, Volatile. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

α-humulene, a sesquiterpene found in essential oils of various plant species, has garnered interest due to its potential therapeutic applications. This scoping review aims to consolidate α-humuleneʼs evidence base, informing clinical translation, and guiding future research directions. A scoping review was conducted of EMBASE, MEDLINE, and PubMed databases up to 14th July 2023. All studies describing original research on α-humulene extraction, as well as pre-clinical and clinical research, were included for review. Three hundred and forty articles were analysed. α-humulene yields ranged from negligible to 60.90% across plant species. In vitro experiments demonstrated cytotoxicity against adenocarcinomas (such as colorectal, pulmonary, breast, prostatic, lung, and ovarian), with varying responses in other cell models. Mechanistic insights revealed its involvement in mitochondrial dysfunction, diminished intracellular glutathione levels, and the induction of oxidative stress. In rodent studies, oral administration of α-humulene at 50 mg/kg reduced inflammation markers in paw oedema and ovalbumin-induced airway inflammation. Intraperitoneal administration of α-humulene (50 – 200 mg/kg) exhibited cannabimimetic properties through cannabinoid 1 and adenosine A2a receptors. α-humulene also exhibited a multitude of properties with potential scope for therapeutic utilisation. However, there is a paucity of studies that have successfully translated this research into clinical populations with the associated disease. Potential barriers to clinical translation were identified, including yield variability, limited isolation studies, and challenges associated with terpene bioavailability. Consequently, rigorous pharmacokinetic studies and further mechanistic investigations are warranted to effectively uncover the potential of α-humulene.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monocyclic SesquiterpenesOils, VolatileHumansAnimalsSesquiterpenesPlant Extracts

Substanzen

Monocyclic SesquiterpeneshumuleneOils, VolatileSesquiterpenesPlant Extracts

Autor:innen und Institutionen

  • Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, UK.
  • Curaleaf Clinic, London, UK.
  • Curaleaf International, London, UK.

ORCID-Profile: Nishaanth Dalavaye

Zitieren

APA

Dalavaye, N., Nicholas, M., Pillai, M., Erridge, S., & Sodergren, M. H. (2024). The Clinical Translation of α-humulene – A Scoping Review. Planta Medica, 90(09), 664-674. https://doi.org/10.1055/a-2307-8183

Vancouver

Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The Clinical Translation of α-humulene – A Scoping Review. Planta Medica. 2024;90(09):664-674. doi:10.1055/a-2307-8183

BibTeX
@article{Dalavaye2024,
  author = {Dalavaye, Nishaanth and Nicholas, Martha and Pillai, Manaswini and Erridge, Simon and Sodergren, Mikael H},
  title = {The Clinical Translation of α-humulene – A Scoping Review},
  journal = {Planta Medica},
  year = {2024},
  volume = {90},
  number = {09},
  pages = {664--674},
  doi = {10.1055/a-2307-8183}
}
Kostenlos starten →